Anavex Life Sciences Corp (AVXL)

[Doc328]

Market not too impresses with the post hoc OLE delayed administration statistical gymnastics.

With an 84% dropout rate from baseline visit, OLE is meaningless to anyone with experience. The sigma-1 receptor and COL24A variants are interesting and might inform inclusion/exclusion data for the P3 (or maybe pre-specified statistical hierarchy of mITT then subgroup). Missling was likely thinking 'maybe if we give them cool names like ABCLEAR1 and ABCLEAR2 (not to be confused with amyloid beta clearance, lol) we can get some more support from retail. I love the COL24A (or should I say ABCLEAR2) GWAS circular data, classic Missling move - test the hypothesis on the same data used to generate it.